The Food and Drug Administration (FDA) on Tuesday issued a warning that the antipsychotic aripiprazo...

A study published today in AJP in Advance suggests the presence of “mixed features” (concurrent mani...

A study in Psychiatric Services in Advance finds that patients with bipolar disorder may be more apt...

The second-generation antipsychotic asenapine may help to reduce mania and the severity of illness i...

Following an acute manic episode, many patients with bipolar disorder are treated with a combination...

In a blog post today, APA CEO and Medical Director Saul Levin, M.D., M.P.A., marked the 25th anniver...

The Food and Drug Administration (FDA) last week approved Vraylar (cariprazine), a dopamine D2/D3 re...

Citicoline reduced cocaine use and was well tolerated by patients with bipolar disorder, according t...

A combination of the antipsychotic olanzapine and the antidepressant fluoxetine proved superior to p...